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Abstract
Background: In examining an initiative to develop and implement new cancer diagnostic pathways in two English
localities, this paper evaluates ‘what works’ and examines the role of researchers in facilitating knowledge translation
amongst teams of local clinicians and policy-makers.
Methods: Using realist evaluation with a mixed methods case study approach, we conducted documentary analysis of
meeting minutes and pathway iterations to map pathway development. We interviewed 14 participants to identify the
contexts, mechanisms and outcomes (CMOs) that led to successful pathway development and implementation.
Interviews were analysed thematically and four CMO configurations were developed.
Results: One site produced three fully implemented pathways, while the other produced two that were partly
implemented. In explaining the differences, we found that a respected, independent, well-connected leader
modelling partnership working and who facilitates a local, stable group that agree about the legitimacy of
the data and project (context) can empower local teams to become sufficiently autonomous (mechanism) to
develop and implement research-based pathways (outcome). Although both teams designed relevant, research-
based cancer pathways, in the site where the pathways were successfully implemented the research team merely
assisted, while, in the other, the research team drove the initiative.
Conclusion: Based on our study findings, local stakeholders can apply local and research knowledge to develop and
implement research-based pathways. However, success will depend on how academics empower local teams to create
autonomy. Crucially, after re-packaging and translating research for local circumstances, identifying fertile environments
with the right elements for implementation and developing collaborative relationships with local leaders, academics
must step back.
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Background
This paper presents a realist evaluation of an initiative to
develop and implement cancer referral pathways from
primary to secondary care in two English localities.
Referring patients for cancer investigation is a challenging
process; many people present to primary care with
symptoms that may suggest cancer but are more frequently
self-limiting and benign [1]. The difficulty for general
practitioners (GPs) is to identify patients who are most
likely to have cancer and refer them for fast-track investiga-
tion, which in the United Kingdom is colloquially termed
the ‘2-week wait pathway’. In recent years, there has been
an expansion of research and policy initiatives around
cancer diagnostics in primary care [2–5].
The knowledge translation initiative examined in this
paper sought to develop and implement referral
pathways for cancer by combining different sources of
knowledge. Knowledge translation is defined as, “a
dynamic and interactive process that includes the
synthesis, dissemination, exchange and ethically sound
application of knowledge to improve health, provide more
effective health products and strengthen the healthcare
system” [6].
The initiative was led by applied health researchers
working collaboratively as the ‘Discovery Programme’
[7] and included most of this paper’s authors (JB, NH,
AG, FW, WH and GR). The aim was to draw on local
knowledge and the research findings of the Discovery
programme and other cancer diagnostic studies to create
research-based pathways for implementation into local
healthcare practice in two English localities. The intended
role of the researchers was to furnish research to reference
groups made up of local stakeholders who could then take
the process forward. To learn more about what worked,
we undertook a realist evaluation [8] and started by identi-
fying the underlying programme theory to understand
why combining academic research with local knowledge
could be effective in the development of improved cancer
pathways. Our initial programme theory was that drawing
together up-to-date cancer diagnostics research (what
works) and presenting it in an accessible format to a
group of local stakeholders and policy-makers who have
the authority to change pathways (context) will stimulate
local ownership (mechanism) leading to the development
of pathways incorporating academic knowledge into local
settings. To evaluate this we employed the following
research questions, (1) How do the people that make up
the reference groups respond to academic research and
how do they work with the Discovery research team who
initiated the process? (2) To what extent do the new
pathways draw on academic research? (3) How successful
are the reference groups in getting the local pathways
implemented? (4) What contextual factors help or hinder
this process?
The initiative delivered very different results in terms
of the design, completion and implementation of the
pathways and subsequent outcomes in the two sites.
Our hope was that a realist evaluation would identify the
contextual factors and mechanisms that differentiated
the two sites and enable guidance on how such initia-
tives might succeed in the future. The paper has been
written in accordance with the RAMESES II reporting
standards for realist evaluations [9].
The initiative – combining academic research and local
knowledge
The initiative was undertaken at the interface between
primary and secondary care – GPs refer patients for
investigation and secondary care teams undertake
diagnostic investigations. There is a balance that has to
be achieved between the two. As mentioned above, most
people with cancer-like symptoms do not have cancer,
and thus GPs face the task of evaluating the risk of non-
referral (missing cancer cases) and too many referrals
(high demand on secondary care investigative and
diagnostic services). Cancer diagnostic research has
sought to improve the balance between referral and
investigation and several research-based tools have been
developed, including risk assessment tools (RATs) and
QCancer [5, 10]. The initiative to develop the pathways
was an extension of this drive to improve cancer
diagnostics in the United Kingdom, but the difficulty lay
in negotiating the complex funding and policy relation-
ships that exist between primary and secondary care. A
further challenge was that, during the initiative, the
organisations that manage 80% of National Health
Service (NHS) funding were radically reorganised across
England, which affected the sites involved [11].
The initiative was the final strand of the Discovery
programme of research and was a pilot for attempting to
put research into healthcare practice. Sites were identi-
fied based on local knowledge and links with Discovery
team members. Local stakeholders were invited by mem-
bers of the Discovery programme to form ‘reference
groups’ in each locality to develop and implement diag-
nostic pathways for cancer. In site 1, Discovery member
AG, who was also the regional cancer lead for public
health, identified and invited reference group members
via existing healthcare forums. In site 2, Discovery study
member GR, an academic clinician, recruited a reference
group chair who then jointly identified and recruited
participants. Both reference groups included primary and
secondary care clinicians, service managers, service
providers and academics from the Discovery programme.
Non-clinical local stakeholders included patient represen-
tatives and members of regional strategic clinical networks
(organisations which combined clinical, service delivery
and patient input to monitor and shape local healthcare
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provision). Permissions were gained from the local health-
care providers for an ‘in principle’ agreement to imple-
ment the new pathways in the two areas.
Pathway development was focused on three cancers in
each locality, namely colorectal, lung and pancreas. These
were chosen by the Discovery research programme team
as the exemplar cancers of the programme because each
contained different challenges in relation to diagnostic
investigation [7].
A key element of the initiative was the introduction of
academic knowledge into the reference groups. The
Discovery team independently devised a customised
information pack for each reference group consisting of
a synthesis of cancer diagnostic information with up to-
date research evidence, local cancer intelligence and
resource materials to inform the process of pathway
design. The documents were adapted for each site with
locally pertinent data and contained:
(1)An overview of the Discovery Programme and the
plans for pathway development initiative.
(2)An overview of the National Cancer Intelligence
Network analysis of routes to cancer diagnosis in
England and relevant, locality-specific data with a
particular focus on the proportion of patients re-
ferred on the appropriate fast track pathways for
cancer investigation.
(3)An overview of primary care referral guidelines and
diagnostic pathways for cancer at national and local
levels.
(4)Details of the resources developed by the Discovery
research team with a particular focus on RATs [12–
14] for the three cancers of interest. RATs are tools
developed to help GPs select patients for cancer
investigation by giving risk scores to particular
symptoms or symptom combinations.
In addition, members of the Discovery team were on
hand to verbally ‘translate’, when necessary.
Methods
This study was approved by the University of Bristol,
Faculty for Medicine and Dentistry, Committee for
Ethics (FCE), Ref: 131448 (9402). Using a case study
approach [15], the evaluation had two main phases.
Firstly, a documentary analysis of the meeting
minutes and decisions taken by the two reference
groups was carried out alongside mapping of the
formation and shape of the pathways. This enabled a
comprehensive understanding of the process and the
overall outcomes in relation to pathway development
and implementation. This process addressed the
following questions:
(1)Did the sites develop new pathways for each of the
specified cancers?
(2)Were the pathways developed within the study time
frame?
(3)To what extent did the sites draw on the research of
the Discovery Programme and/or other recent
cancer diagnostic research?
(4)Were the developed cancer diagnostic pathways
implemented?
JB, NH and JR met and examined documents associated
with pathway development, including reference group
minutes and the associated iterations of the pathway. This
documentary analysis generated accounts of the pathway
development in each locality, which fed into a compara-
tive matrix table including data on both pathway content
and timing (Table 1). The table also served to inform the
development of draft context–mechanism–outcome
(CMO) configurations, which, along with the programme
theory, shaped our strategy for data collection in the
second phase of the study.
This second phase used qualitative interviews with pur-
posefully sampled participants from each reference group
at the two sites, which enabled in-depth insight into the
context and mechanisms at play, for example, the ration-
ale behind the decisions that were taken in relation to
pathway development. Participants were sampled pur-
posefully to ensure representation from clinicians (pri-
mary and secondary care), service managers and non-
clinical stakeholders. Participants were invited by e-mail,
and interviews took place between December 2014 and
February 2015, which was approximately 7 months (site 1)
and 12 months (site 2) after the reference groups had
completed the main aspects of pathway development. In-
terviews were undertaken by JR, who was not a member
of the Discovery team, and broadly followed a topic guide
but were not restricted to it (Additional file 1). The topic
guide was developed from an assessment of the pathway
development documentation described above and the
programme theory that was outlined at the start of the
evaluation. Formal consent to participate was taken prior
to the interview.
Twenty members of the reference groups were
invited via e-mail, of which 14 agreed to participate
(Table 2) and 6 did not respond. Most interviews
took place over the phone (n = 10) with the remain-
der face to face (n = 4). Interviews were audio
recorded, transcribed verbatim and fully anonymised.
Interview transcripts were analysed thematically [16].
Initially, transcripts were read by JB and JR, and an
initial coding frame was developed. Two transcripts were
double coded by JB and JR, and the codes were further
refined. JR coded the full set of transcripts using NVivo
version 10 [17]. Coded data were organised into CMO
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configurations (e.g. codes for ‘working relationships’ and
‘leadership’ were categorised as contextual factors). JB,
JR and NH engaged in a process of testing and refining
the programme theory and developing CMOs, at regular
research meetings as data analysis continued, until the
final CMOs and revised programme theory were agreed.
These are presented below.
Results
Pathway development – overview of outcomes
Table 1 provides an overview of the differences in the
pathway content in the two sites by cancer type. Path-
ways were developed in both sites for the diagnosis of
lung and pancreas cancers. Both aimed to accelerate
diagnosis by employing simultaneous referrals for tests
and investigations alongside referrals to secondary care
clinical teams. This would enable a patient to present for
specialist assessment in secondary care with relevant
tests completed. However, the reference group in site 1
did not reach agreement on a new pathway for
suspected colorectal cancer. Thus, only two pathways
were developed in site 1 rather than three, as in site 2.
A second major difference was the inclusion (or not) of
RATs. In site 1, the reference group stopped short of
formally incorporating RATs as part of the assessment for
referral and instead included them as reference tools for
guidance. However, in site 2, the reference group
incorporated RATs from the Discovery research programme
into all three pathways.
There was a difference in the time it took to develop
the pathways. The pathways in site 1 took 3 months
longer to be developed and also involved twice as many
meetings (Table 3).
However, perhaps the most important difference
between the two sites was that the pathways were not fully
implemented in site 1. Technical difficulties were encoun-
tered loading the details on the electronic GP referral
system and these were never fully integrated; the referral
forms still gave standard national guidance and did not
give the option for simultaneous referral, which was a key
aspect of the newly designed pathways. In short, when site
1 GPs logged onto the system there was no clear way of
using the new pathways, whereas in site 2 GPs were able
to fully access the re-designed pathways.
Both sites held launch events to promote the pathways
(Table 3), but there were differences in the role of the
Discovery team. In site 2, the launch was organised by
reference group members and drew on pre-existing
event processes and organisational structures within the
local healthcare system. Around 230 GPs attended as
Table 1 Comparing pathway modifications: changes and adaptions made to diagnostic pathways
Site 1 Site 2
Lung
• Remove minimum time threshold for referral
• Introduction of RATs as reference tool
• For persistent high risk symptoms OR suspicious CXR patient referred
simultaneously to 2-week wait pathway 2WW clinic AND CT scan 2WW
• Formal use of RATs alongside existing national NICE guidelines including a
recommended risk assessment threshold of 2%
• Option to do 2WW and simultaneous CXR for highly suspicious symptoms
• Radiology given initiative to initiate 2WW referral and CT scan following
suspicious CXR
Pancreas
• RAT introduced as reference tool
• Built on previous pilot by secondary care trust
• Splits jaundice into a separate pathway (recognition of high risk)
• Fast track for jaundice and suspicion of cancer
• Simultaneous referral for CT and 2WW on non-jaundice pathway for
high risk symptoms
• Fast track route in for GP generated ultrasound referrals w/suspicion
of malignancy
• Formal use of RAT and threshold score for 2WW
• High risk symptoms go direct to CT scan followed by consultant
review
• Below national NICE guidance and RAT threshold consider
abdominal US scan, if suspicious into 2WW
Colorectal
• No change to national NICE guidelines • Formal introduction of RAT with lower threshold than national
NICE guidelines
• For high risk symptoms and patients that meet the safety criteria
GPs given a direct access to colonoscopy option
2WW 2-week wait referral pathway, CT computed tomography scan, CXR chest X-ray, GP general practitioner, NICE National Institute for Health and Care Excellence,
RAT risk assessment tool, US ultrasound
Table 2 Interviews
Primary care Secondary care Non-clinical Total
Interviewed (invited) Interviewed (invited) Interviewed (invited) Interviewed (invited)
Site 1 2 (3) 5 (7) 1 (1) 8 (11)
Site 2 3 (3) 1 (4) 2 (2) 6 (9)
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the launch was tied into a regular GP training session
and GPs had protected time to attend. However, in site
1, the Discovery research team organised the launch.
Although the research team advertised in a widely
distributed electronic newsletter, they were not able to
tap into the same local infrastructure and only eight GPs
attended. In site 1, there was a stronger association
of the new pathways with the research team, which
did not carry the same level of ‘official’ (NHS)
endorsement or backing.
The CMO of pathway development
Data analysis from the two phases led to the production
of four CMO configurations which identified the elements
Table 3 Reference groups timing and launch
Site 1 Site 2
Meeting 1
Date of meeting 29/07/2013 01/09/2013
Meeting
structure
3 sub-groups established for each cancer pathway
Chaired by Discovery research lead, 1 PPI member
3 sub-groups established for each cancer pathway
Chaired by local stakeholder
1 observer from National Cancer Action Team, 2 PPI members
and 2 members of Discovery research team
Post-meeting
actions/activity
Discovery research team collate minutes and design pathways Local reference group members action the pathway design
Meeting 2
Date of meeting 11/11/2013 13/11/2013
Meeting structure No sub-groups – pathway changes reviewed by full
reference group
Chaired by Discovery research team lead
Significant change in membership/attendance
No sub groups – pathway changes reviewed by full
reference group
Chaired by local stakeholder
2 Discovery researchers present
Meeting outcome Pathways presented by Discovery research team not
accepted by reference group and required further work
New pathways considered and accepted with minor
amendments agreed prior to implementation
Post-meeting
actions/activity
Discovery team liaise with clinical leads from reference
group to redraw pathways
Local reference group members amend pathways
Meeting 3
Date of meeting 21/01/2014 N/A – pathway design completed
Meeting structure No sub-groups – pathway changes reviewed by full
reference group
Chaired by Discovery research team lead
Significant change in membership
Meeting outcome Pathways submitted by Discovery team were not fully
accepted by reference group; further work required
Post-meeting
actions/activity
Discovery team liaise with clinical leads from reference
group to redraw pathways
2 meetings with colorectal sub-group failing to reach
agreement
Meeting 4
Date of meeting 11/03/2014 N/A – pathway design completed
Meeting structure Pathway changes reviewed by full reference group
Chaired by Discovery researcher
Meeting outcome Lung and pancreas pathways subject to further amendment and
tentatively agreed
No agreement on colorectal pathway
Launch and promotion of modified cancer pathways
Launch
meeting date
01/05/2014 14/02/2014
Meeting
details
8 GPs in attendance
No protected GP time, i.e. GPs attending in their own time
Discovery team lead with support from clinical reference
group members
~230 GPs attended
Protected time for GPs as part of ‘time in time out’
training day
Pathways presented by reference group team
Short intro from Discovery researcher
GP general practitioner, PPI patient and public involvement representative, N/A not available
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that contributed to successful pathway development and
implementation, and explained the differences between
the two sites.
CMO 1. A stable group made up of the ‘right’ people who
have previously worked together successfully (context)
facilitates a shared purpose (mechanism), which leads to
effective and timely pathway development (outcome)
Different patterns of attendance emerged from the refer-
ence group meetings (Table 4). The site 1 group had very
little compositional stability, whereas in site 2 there were
few changes of personnel. Table 4 shows the change in
proportion of roles that populated the two groups over
the duration of pathway development. The site 2 group
change was < 10% for all roles whereas in site 1 there was
an increase in secondary care membership of 19% across
the four meetings (this was as high as 61% at meeting 3).
There was also a decrease in primary care membership of
22% in site 1.
The importance of group composition was highlighted
by a site 2 member,
“I think the benefit of it obviously was getting people in
the same room at the same time so obviously having a
mix of different people from primary care, from
secondary care, from trust management, that obviously
needs to happen if you’re going to try and make changes
like the ones that have been made … I don’t think it
would have worked so well if you had – if you didn’t
have the right people in the room.” (Site 2, 004)
The perception of a well-balanced reference group in
site 2 was underpinned by a legacy of participants having
previously worked together on change and implementa-
tion initiatives. There was a shared network and history to
build on which conveyed a feeling of continuity between
the Discovery programme initiative and previous projects.
There was also a legacy of developing policy change in site
2, which conveyed a sense of continuity between the
Discovery work and previous change initiatives,
“I think the personal relationships between the
participants were quite important, that these were
people who’ve worked together for some time and who
have interacted through the cancer network previously
and I think that helped.” (Site 2, 003)
The strong group identity at site 2 appeared to
override the members’ individual agendas and organ-
isational interests,
“I’ve always been struck by the collaborative way in
which clinicians come together on cancer services. …
they genuinely behave as if it’s a service that’s
important not their organisation. We do talk about
people taking their team’s shirt off as they come in the
door and they do, you know, in these workshops that
we’ve organised over the years people are very keen to
talk about the service and patients not the
organisational politics but it inevitably on some
occasions does come into play.” (Site 2, 003)
In contrast, there were several negative reflections on
the composition of the site 1 group. A common percep-
tion was that key people were missing, but there was no
consensus on who should have been present. For some,
it was the absence of secondary care clinicians and for
others it was a lack of primary care clinicians. Moreover,
while some members in site 1 had previously worked
together, the group as a whole had not and the constant
fluidity of membership made it difficult to establish a
shared purpose.
CMO 2. Respected, independent and well-connected local
leaders who model partnership working across organisational
boundaries (context) foster engagement from reference group
members (mechanism) who are proactive in pathway design
and development
In site 2, there was evidence of respected and trusted
leaders within the reference group. More than one
person led the process in site 2. Clinical leadership came
Table 4 Reference group composition
Site 1 Site 2
Profession/role Meeting 1 Meeting 2 Meeting 3 Meeting 4 Change (%) Meeting 1 Meeting 2 Change (%)
Secondary care clinician 4 (31%) 6 (46%) 11 (61%) 6 (50%) +19% 5 (28%) 3 (20%) –8%
Secondary care manager 0 (0%) 2 (15%) 3 (17%) 1 (8%) +8% 1 (6%) 1 (7%) +1%
Primary care clinician 4 (31%) 2 (15%) 0 (0%) 1 (8%) –22% 5 (28%) 5 (33%) +6%
Research team 4 (31%) 3 (23%) 4 (22%) 3 (25%) –6% 2 (11%) 2 (13%) +2%
Clinical network 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0% 3 (17%) 2 (13%) –3%
Patient/public 1 (8%) 0 (0%) 0 (0%) 1 (8%) +1% 2 (11%) 2 (13%) +2%
Total 13 13 18 12 18 15
Banks et al. Health Research Policy and Systems  (2017) 15:103 Page 6 of 11
from a GP with established cancer-related interests with
several organisational bodies in the region,
“I guess the lead GP, if we could describe as such,
would be XX … he’s very committed, he’s a very
committed GP to cancer and I think he is now, I think
at that point he was becoming an executive – he was
becoming part of the executive of the [policy-making
organisation] and he was leading on cancer so that
was extremely helpful.” (Site 2, 003)
Further clinical leadership came from a clinician with
a high profile and a previous leadership role within the
cancer networks,
“We are lucky enough as well, we always mention
about YY. He used to be the cancer network director
but he’s still running the clinical – he’s actually
running the clinical network now so cancer’s one of it
and he is very good at bringing people together … YY
actually helped us – helped myself and some of the key
people learn how to work together and now when you
see that come along we actually knew how to do it and
we could take it forward. YY is absolutely crucial.”
(Site 2, 006)
Having successfully worked across boundaries, particu-
larly primary and secondary care, these leaders provided
valuable learning on partnership working, which was
beneficial to the site 2 reference group, who were also
drawn from different healthcare sectors and clinical
specialities. These leaders helped site 2 reference group
members know ‘how to do it’ and fostered proactive
engagement. This proactivity was evidenced in the
documentary analysis (presented in Table 3), with site 2
reference group members taking most of the responsibil-
ity for the work between meetings, while site 1 reference
group relied on significant input from the Discovery
research team, including taking forward the actions of
previous meetings.
In site 1, leadership was compromised for several
reasons. The chair of the reference group was also
part of the Discovery research team, so the site 1
group did not benefit from the perception of inde-
pendent leadership present in site 2. Additionally, a
major re-organisation of the health service [18], which
was contemporaneous with the study, led to the chair
changing her organisational base and a destabilisation
of institutional ties and connections. This resulted in
a perceived lack of continuity with key sectors of the
local healthcare economy, partnership working was
frustrated and the new association with different insti-
tutions further compromised the perception of inde-
pendence. Consequently, engagement was poorer.
CMO 3. A clear understanding and acceptance of the aims
of the project, including the legitimacy of research data and
the process of pathway development (context), provides a
basis for agreement (mechanism), which facilitates a
pathway incorporating research evidence (outcome)
In site 2, there was a clearer understanding, acceptance
and consensus of why the work needed to be undertaken,
“Yes, we were aware that late diagnosis was a
significant problem; in fact it still is across the entire
health service and in our area in particular. We could
see that there were areas doing better than us and this
was reflected in mortality statistics we were getting
from public health.” (Site 2, 009)
In site 1, respondents agreed with and supported the
aims of improving cancer diagnosis and believed im-
provements were possible, but some thought the project
was focusing on the wrong part of the pathway. The
overall initiative, its legitimacy and aims were brought
into question much more in site 1.
“There was some concerns as to how realistic the
project was in its overall aims, could we actually make
a difference in such a short time and then measure it
and I think we all had concerns about that … there
was an aim to get it rolled out across the whole of [site
1] how realistic was that to influence how GPs
practice, ‘cos we know it’s very difficult to change
people’s practice and to change everyone in [site 1] to
suddenly changing pathway was quite an ask, and
how robust therefore the data be so I think we were a
bit concerned that the methodology, whether it was
actually robust.” (Site 1, 008)
This contributed to a negative or defensive attitude to
the initiative,
“In terms of, you know, spending anyone’s money on
the lung cancer part of this I thought that probably
wasn’t the most prudent way to do it and I’d much
rather been given a chunk of money and been told to
go and do some social marketing to try and influence
things … I think we needed to shape it because it
would have been even worse, wouldn’t it, if none of us
had turned up.” (Site 1, 013)
The differing perspectives on the initiative and the
Discovery team were also reflected in the way that the
local reference document was viewed in each site. As
described above, the research team compiled the docu-
ments prior to the first meeting in both sites. Site 2
viewed the reference document as a platform to start the
process of pathway design; they recognised the contents
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as valid and relevant, whereas in site 1 the contents of
the documentation and research data were contested
and their relevance to the local area questioned,
“There’s public health involvement which to my mind
was quoting figures that I didn’t recognise … I think
you have to use very well validated data to show what
the problem is … I know that our data is very robust
and I can tell you exactly how many cases of lung
cancer I saw last year presented as an emergency and
it’s not many.” (Site 1, 013)
CMO 4. The research team take a minor, non-directive role in
the reference group (context), which encourages local
ownership (mechanism) and leads to proactive pathway
design and support for implementation (outcome)
The Discovery programme research team adopted dif-
ferent approaches to their relationship with the
reference groups and their role in developing the
pathways. In both sites, the research team compiled,
distributed and ‘translated’ the information packs after
identifying local leaders and stakeholders to take the
initiative in developing and designing the pathways.
Then, in site 2, the research team stepped back from
the process. However, in site 1, the research team had
a major role in every meeting as a Discovery team
member chaired the meetings and other Discovery
researchers regularly attended and were actively
involved in pathway design (Table 3). Crucially, as the
process faltered in site 1 so the research team tried
to rescue the initiative by becoming more prominent
in shaping the pathways. In site 2, the research team
were much more in the background.
Consequently, the process was viewed very differently
in the two sites. In site 1, it was perceived as a top-down
process led by the research team who were trying to
‘impose’ a set of ideas on the local healthcare system,
“It felt very much like we were being told you have to do
this rather than here’s a project, here’s our aims, we’d
like to do this, can you support us and help us, you
know, let’s do this together. I think there perhaps wasn’t
so much of a collaborative kind of feeling in the way it
was done. It was always a bit vague.” (Site 1, 002)
Conversely, in site 2, the ‘light touch’ approach taken
by the research team led to a feeling of ownership by the
reference group, which gave momentum and energy.
The research team remained external yet supportive to
the reference group so that when the revised pathways
were fed back at subsequent meetings, the pathways
were recognised as belonging to the reference group,
rather than a product of the Discovery team researchers.
Discussion
Summary of results
We identified four CMOs that were instrumental in
combining academic research with local knowledge to
feed into the development and implementation of new
pathways for cancer diagnosis. A key finding was that
success was greater when pathway development and
implementation was performed by local stakeholders
who were more autonomous from the research team.
Figure 1 sets out these CMO configurations.
Our original programme theory suggested that com-
bining academic and local knowledge would foster local
ownership leading to the successful development and
implementation of research-based pathways. However,
on completion of data collection and analysis, we
recognised that the furnishing of knowledge alone was
insufficient and that engendering ‘ownership’ was more
nuanced. The empowerment and autonomy of the local
teams were essential to the success of the initiative.
Thus, our revised programme theory is that a respected,
independent, well-connected leader who models partner-
ship working and facilitates a local, stable group with a
strong identity that agrees about the legitimacy of the
project aims, process and data, working with a research
team who take a minor, non-directive role (context) can
empower local teams to become sufficiently autonomous
(mechanism) to develop and implement research-based
pathways (outcome).
The more successful site had a balanced, stable member-
ship with a history of working together, which created a
strong sense of identity and fostered a greater sense of
shared purpose – a mechanism that helped drive the
process. Moreover, site 2 benefited from respected, well-
connected and independent local leaders with excellent
collaboration skills who had consistent inter-organisational
ties for the duration of the project. This modelling of
partnership-working empowered site 2 reference group
members to gain the confidence and skills necessary to
make the project a success. Possibly because these leaders
were trusted, this helped the reference group to understand
and accept the legitimacy of the information pack in a way
that the research team in site 1 could not. Moreover, site 2
leads had strong roots in the local clinical networks and
brought an independence to the group, i.e. they were not
seen representing any organisational interests other than
the improvement of cancer services. Their autonomy gave
the process momentum that was lacking in the other site,
and more work was completed between meetings without
input from the research team.
Site 1 provided a stark contrast. With less stable mem-
bership, which did not have an established history of
working together, a weak sense of identity and changing
local structures, the pathway development process became
almost a defence against the perceived imposition of new
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pathways by the research team, as the researchers
attempted to compensate for key missing elements. The
research team were not seen as independent or credible
and dialogue was more adversarial. The reference group
questioned the need for reform at ‘their’ point of the path-
way and were sceptical of the research materials that were
used to start the process; there was not the shared under-
standing that existed in site 2. Further, political changes
with re-organisations had a much more disruptive effect
at site 1, where leadership positions were affected. Site 1
reference group members felt neither empowered nor
autonomous. This does not mean that knowledge
translation should be avoided in more complex local-
ities during unstable times, but it is an indication of
where it might be easier.
Implications of findings
This paper raises important questions about re-
searchers’ roles in dissemination and implementation.
The Discovery research team consisted of applied
health services researchers with little expertise in
knowledge translation. Increasingly, academics will
also need to acquire knowledge translation skills as
funding bodies are placing greater emphasis on viable
dissemination plans and core university funding relies
on demonstrations of ‘impact’ within the United Kingdom
[18, 19]. Just as all health services academics have had to
address issues of patient engagement with their research,
so they will need skills in knowledge translation; it is
becoming everybody’s business.
Consequently, researchers are being asked to adopt
new roles. Mode 1 is the default with the researcher as a
‘reflective scientist’, but there is the emerging role of
Mode 2, with the researcher as an ‘intermediary’ or
‘facilitator’ [20]. For example, there is an account of
Mode 1 Norwegian researchers acting in Mode 2 roles
to set up a randomised controlled trial in cooperation
with policy-makers, only for the researchers to become
frustrated as the policy-makers implemented the less
effective intervention [21]. To help educate and up-skill
researchers, more studies are needed, like this one,
whereby researchers experiment and evaluate how they
can operate effectively within the world of Mode 2
without prejudicing the quality of their science.
The intention of the Discovery researchers was to be
responsible for the synthesis and presentation of
research and local data, and leave local stakeholders in
charge of pathway development and implementation.
The research team hoped to identify and cultivate
collaboration with an enthusiastic local leadership, who
would convene the reference group and drive the imple-
mentation forward. Then, the Discovery team intended
to step back. This approach worked successfully in site
2, where the key elements of successful pathway
development and implementation were in place, so that
reference group members felt sufficiently empowered
and autonomous. The researchers attempted to use the
same approach in site 1, but with two key differences –
the key local contextual elements were not in place and
the research team took on a leadership and active design
role, which failed to work.
The key learning point was that researchers cannot
compensate for the missing elements of successful know-
ledge translation. If those elements do not exist, given the
challenges of implementation, research teams may need to
move on to more fertile ground. Local stakeholders, not
researchers, have to undertake implementation. Similarly,
researchers need to be aware that initial enthusiasm may
ebb. However, if in an effort to save the project, research
teams attempt a rescue operation, they are unlikely to
Fig. 1 Context–mechanism–outcome configurations
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achieve their overall goal – that of seeing the results of
their research implemented.
Strengths and limitations
A major strength of this research was that two sites were
studied, such that potential CMOs could be contrasted
and compared to create more robust theories about
what worked. However, these CMOs need further testing
elsewhere to provide greater confidence in the generalis-
ability of findings.
An unusual aspect was that the main interviewer was
a policy-maker. With his experience of managing change
in healthcare economies, he brought extra depth to the
data collection, analysis and interpretation process.
A key challenge of this study was the continual
changes in healthcare policy and arrangements nation-
ally and locally that required the pragmatic adaptation of
the research team.
Conclusion
Our study adds useful information to the literature about
the role that applied health services researchers can adopt
to encourage implementation of research findings, and the
contextual factors that are more likely to lead to local
uptake. We found that, despite a comparable ‘input’ of
locally tailored research evidence, outcomes for the two
sites were different. Although both local stakeholder groups
designed relevant, evidence-based cancer pathways, the
research team assisted in the site where the pathways were
successfully implemented, while in the other the research
team drove the initiative. Consequently, the local teams
were not empowered or autonomous, which meant that
the resulting pathways were never ‘owned’ locally nor
implemented. To facilitate successful implementation,
research teams need to re-package the scientific evidence
for local circumstances, ‘translate’ that evidence verbally,
identify fertile environments with the right elements
for implementation, develop a collaborative relation-
ship with a local leader(s) to take action and, then,
importantly, step back.
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